- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT01264627
A New Translational Tool for Studying the Role of Breathing in Meditation
20 november 2020 bijgewerkt door: University of California, San Francisco
Project Inspire: A New Translational Tool for Studying the Role of Breathing in Meditation
A recent National Health Interview Survey reported that breathing exercises were the second most common complementary and alternative medicine practice in the United States, following only the use of "natural products."
With such widespread interest in breathing exercises, alone or as a component of practices such as meditation, a need exists for research that examines not only its efficacy, but also investigates potential mechanisms of action.
Indeed, a recent National Center for Complementary and Alternative Medicine (NCCAM) Meditation Workshop recommended research to clarify biological pathways by which meditation practices, including breathing exercises, can impact health.
To explore mechanisms underlying the health effects of breathing exercises, new translational tools are needed that can measure breathing patterns in both the clinic and natural environment.
The primary objective of the present proposal is the application of a new technology to the investigation of pathways by which breathing exercises can affect health.
For this project, the health-related outcome measure to be studied is a major cardiovascular risk factor, blood pressure.
Studie Overzicht
Toestand
Voltooid
Conditie
Interventie / Behandeling
Studietype
Ingrijpend
Inschrijving (Werkelijk)
99
Fase
- Niet toepasbaar
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
50 jaar en ouder (Volwassen, Oudere volwassene)
Accepteert gezonde vrijwilligers
Nee
Geslachten die in aanmerking komen voor studie
Vrouw
Beschrijving
Inclusion Criteria
- Mean 24-hr SBP: 130-139 mmHg
- Female
- > 50 years of age
- Post menopausal, defined as greater than or equal to one year without a menstrual cycle.
- Body Mass Index (BMI): 19-31
- English speaking (Patients not able to read and speak English will be excluded as the behavioral group interventions are conducted in English)
- Has a personal physician
Exclusion Criteria (Individuals will be filtered in the KP OSCA database according to the following ICD-9 codes):
Respiration:
- 491.X chronic Bronchitis incl COPD
- 492.X emphysema
- 493.X asthma
- 494-496; 500-519: all kinds of chronic pulmonary conditions
Cardiovascular:
- 404.9 chronic ischemic heart disease
- 425.X cardiomyopathies
- 428.X heart failure
- 430-438 cerebrovascular diseases
Kidney:
- 582-583 chronic glomerulonephritis
- 584-588 renal failure
Liver:
- 571.X chronic liver disease and cirrhosis Smoker: 305.1
Psychiatric:
- 290-299 dementia/schizophrenia/ psychoses…
- 303, 304 alcohol or drug dependence
- 317-319 mental retardation
Medications:
- All blood pressure medications
- All tranquilizers, benzodiazepins if prescribed regularly, e.g. every month
- All narcotics if prescribed regularly, e.g. every month
Other:
- Plan to relocate residence outside recruitment area during the intervention or follow- period
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Preventie
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Enkel
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Mindful Breathing (MB)
The MB intervention is based off of the Mindfulness Based Stress Reduction Program developed by Jon Kabat-Zinn.
Participants will be organized into cohorts of eight, and attend eight weekly MB sessions.
Mindful breathing consists of closely "following the breath," throughout inhalation and exhalation, sustaining moment-to-moment awareness on the breathing process, and passively observing thoughts, affective states, perceptions and events, from a non-evaluative, non-judgmental perspective.
No other intervention is included.
No FDA drug or device is involved.
|
The Mindful Breathing (MB)intervention is based on MBSR developed by Jon Kabat-Zinn.
Participants will attend 8 individual weekly MB sessions.
MB consists of closely "following the breath," throughout inhalation and exhalation, sustaining moment-to-moment awareness on the breathing process, and passively observing thoughts, affective states, from a non-evaluative or judgmental perspective.
As attention wanders to concerns or thoughts, participants will be instructed to acknowledge and accept these without evaluation and return the focus of attention back to breathing.
Participants in MB will have their breathing rate and PetCO2 monitored during the 8 training sessions with a breathing monitor.
|
|
Ander: Usual Care (UC)
Usual Care consists of the standard care made available to participants through their primary physician.
No intervention is included.
No FDA drug or device is involved.
|
This control intervention is designed to account for the effects of nonspecific factors such as enrollment in a study to enhance health with the associated expectancy effects, staff attention, and measurement procedures including the monitoring of PetCO2 and (Blood Pressure) BP, and completion of questionnaires.
Participants who are randomly assigned to the Usual Care condition will receive care as usual for the management of their prehypertensive condition.
UC participants will receive their usual care and have access to all Kaiser Permanente (KP) health education resources, such as KP's interactive healthcare guide, and online "Healthy Lifestyle Programs".
We will assess the extent to which participants in both MB and UC used these resources.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Blood Pressure
Tijdsspanne: Up to Week 25
|
Measured using Ambulatory, 24-Hr BP monitor
|
Up to Week 25
|
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Clinic (resting) blood pressure
Tijdsspanne: Up to Week 25
|
Up to Week 25
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Onderzoekers
- Hoofdonderzoeker: Margaret A Chesney, PhD, University of California, San Francisco
Publicaties en nuttige links
De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start (Werkelijk)
1 februari 2011
Primaire voltooiing (Werkelijk)
31 juli 2017
Studie voltooiing (Werkelijk)
31 augustus 2017
Studieregistratiedata
Eerst ingediend
15 december 2010
Eerst ingediend dat voldeed aan de QC-criteria
21 december 2010
Eerst geplaatst (Schatting)
22 december 2010
Updates van studierecords
Laatste update geplaatst (Werkelijk)
24 november 2020
Laatste update ingediend die voldeed aan QC-criteria
20 november 2020
Laatst geverifieerd
1 november 2020
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 1R01AT005820 (Subsidie/contract van de Amerikaanse NIH)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Nee
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .